eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response

Acta Neuropathologica

Volumn 133, Issue 1, 2017, Pages 101-119

  Jan, Asad ^a,b   Jansonius, Brandon ^b   Delaidelli, Alberto ^a,b   Somasekharan, Syam Prakash ^b   Bhanshali, Forum ^c   Vandal, Milène ^d   Negri, Gian Luca ^b   Moerman, Don ^a   MacKenzie, Ian ^a   Calon, Frédéric ^d   Hayden, Michael R ^c   Taubert, Stefan ^c   Sorensen, Poul H ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alzheimer s disease; A oligomers; eEF2K; mRNA translation; NRF2; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ELONGATION FACTOR 2 KINASE; REACTIVE OXYGEN METABOLITE; SEROTONIN; TRANSCRIPTION FACTOR NRF2; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); EEF2K PROTEIN, HUMAN; EEF2K PROTEIN, MOUSE; ENZYME INHIBITOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAENORHABDITIS ELEGANS; CELL VIABILITY; CONTROLLED STUDY; DENDRITE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; FRONTAL CORTEX; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NERVE CELL PLASTICITY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; FRONTAL LOBE; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; TRANSGENIC ANIMAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CAENORHABDITIS ELEGANS; CELL SURVIVAL; CELLS, CULTURED; ELONGATION FACTOR 2 KINASE; ENZYME INHIBITORS; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MALE; NEURONS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; REACTIVE OXYGEN SPECIES;

EID: 84991711444     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1634-1     Document Type: Article

References (68)

1. Alonso-Nanclares L, Merino-Serrais P, Gonzalez S, DeFelipe J (2013) Synaptic changes in the dentate gyrus of APP/PS1 transgenic mice revealed by electron microscopy. J Neuropathol Exp Neurol 72:386–395. doi:10.1097/NEN.0b013e31828d41ec
2. Baxter PS, Bell KF, Hasel P, Kaindl AM, Fricker M, Thomson D et al (2015) Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat Commun 6:6761. doi:10.1038/ncomms7761
3. Bender CL, Yang Q, Sun L, Liu SJ (2016) NH125 reduces the level of CPEB3, an RNA binding protein, to promote synaptic GluA2 expression. Neuropharmacology 101:531–537. doi:10.1016/j.neuropharm.2015.03.017
4. Boyce M, Py BF, Ryazanov AG, Minden JS, Long K, Ma D et al (2008) A pharmacoproteomic approach implicates eukaryotic elongation factor 2 kinase in ER stress-induced cell death. Cell Death Differ 15:589–599. doi:10.1038/sj.cdd.4402296
5. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77:71–94
6. Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85:705–717. doi:10.1016/j.bcp.2012.11.016
7. Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B et al (2012) Critical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 109:8740–8745. doi:10.1073/pnas.1206171109
8. Carrera I, Etcheverria I, Li Y, Fernandez-Novoa L, Lombardi V, Vigo C et al (2013) Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-beta vaccine. Biomed Res Int 2013:709145. doi:10.1155/2013/709145
9. Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF et al (2011) 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem 286:43951–43958. doi:10.1074/jbc.M111.301291
10. Chu HP, Liao Y, Novak JS, Hu Z, Merkin JJ, Shymkiv Y et al (2014) Germline quality control: eEF2K stands guard to eliminate defective oocytes. Dev Cell 28:561–572. doi:10.1016/j.devcel.2014.01.027
11. Chuang TT (2010) Neurogenesis in mouse models of Alzheimer’s disease. Biochim Biophys Acta 1802:872–880. doi:10.1016/j.bbadis.2009.12.008
12. De Strooper B, Karran E (2016) The cellular phase of Alzheimer’s disease. Cell 164:603–615. doi:10.1016/j.cell.2015.12.056
13. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112. doi:10.1038/nrm2101
14. Habas A, Hahn J, Wang X, Margeta M (2013) Neuronal activity regulates astrocytic Nrf2 signaling. Proc Natl Acad Sci USA 110:18291–18296. doi:10.1073/pnas.1208764110
15. Hamilton A, Vasefi M, Vander Tuin C, McQuaid RJ, Anisman H, Ferguson SS (2016) Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an alzheimer disease mouse model. Cell Rep 15:1859–1865. doi:10.1016/j.celrep.2016.04.077
16. Harada A, Teng J, Takei Y, Oguchi K, Hirokawa N (2002) MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J Cell Biol 158:541–549. doi:10.1083/jcb.200110134
17. Harder B, Jiang T, Wu T, Tao S, de la Vega MR, Tian W et al (2015) Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. Biochem Soc Trans 43:680–686. doi:10.1042/BST20150020
18. Heise C, Gardoni F, Culotta L, di Luca M, Verpelli C, Sala C (2014) Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons. Front Cell Neurosci 8:35. doi:10.3389/fncel.2014.00035
19. Hobert O (2003) Behavioral plasticity in C. elegans: paradigms, circuits, genes. J Neurobiol 54:203–223. doi:10.1002/neu.10168
20. Jan A, Adolfsson O, Allaman I, Buccarello AL, Magistretti PJ, Pfeifer A et al (2010) A{beta}42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete A{beta}42 species. J Biol Chem. doi:10.1074/jbc.M110.172411
21. Jan A, Hartley DM, Lashuel HA (2010) Preparation and characterization of toxic A[beta] aggregates for structural and functional studies in Alzheimer’s disease research. Nat Protocols 5:1186–1209. http://www.nature.com/nprot/journal/v5/n6/suppinfo/nprot.2010.72_S1.html
22. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170
23. Johnson DA, Johnson JA (2015) Nrf2–a therapeutic target for the treatment of neurodegenerative diseases. Free Radic Biol Med 88:253–267. doi:10.1016/j.freeradbiomed.2015.07.147
24. Keith D, El-Husseini A (2008) Excitation control: balancing PSD-95 function at the synapse. Front Mol Neurosci 1:4. doi:10.3389/neuro.02.004.2008
25. Kenney JW, Moore CE, Wang X, Proud CG (2014) Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul 55:15–27. doi:10.1016/j.jbior.2014.04.003
26. Kessels HW, Nabavi S, Malinow R (2013) Metabotropic NMDA receptor function is required for beta-amyloid-induced synaptic depression. Proc Natl Acad Sci USA 110:4033–4038. doi:10.1073/pnas.1219605110
27. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
28. Lansbury PT, Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774–779. doi:10.1038/nature05290
29. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M et al (2013) The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 153:1064–1079. doi:10.1016/j.cell.2013.04.055
30. LeVine H 3rd, Walker LC (2016) What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiol Aging 42:205–212. doi:10.1016/j.neurobiolaging.2016.03.019
31. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62:788–801. doi:10.1016/j.neuron.2009.05.012
32. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer’s disease brain. FEBS J 272:4211–4220. doi:10.1111/j.1742-4658.2005.04833.x
33. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. doi:10.1038/nature05292
34. Liu R, Proud CG (2016) Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. Acta Pharmacol Sin 37:285–294. doi:10.1038/aps.2015.123
35. Lu T, Aron L, Zullo J, Pan Y, Kim H, Chen Y et al (2014) REST and stress resistance in ageing and Alzheimer’s disease. Nature 507:448–454. doi:10.1038/nature13163
36. Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P et al (2014) Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta. J Neurosci 34:12230–12238. doi:10.1523/JNEUROSCI.1694-14.2014
37. Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, Messa M et al (2011) The molecular assembly of amyloid abeta controls its neurotoxicity and binding to cellular proteins. PLoS One 6:e24909. doi:10.1371/journal.pone.0024909
38. Margie O, Palmer C, Chin-Sang I (2013) C. elegans chemotaxis assay. J Vis Exp e50069. doi:10.3791/50069
39. Ming GL, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70:687–702. doi:10.1016/j.neuron.2011.05.001
40. Mitsuishi Y, Motohashi H, Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2:200. doi:10.3389/fonc.2012.00200
41. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421. doi:S0896627303004343 [pii]
42. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA et al (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66:75–85. doi:10.1097/nen.0b013e31802d6da9
43. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P et al (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. JNeurosci 25:11061–11070
44. Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S et al (2014) HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc Natl Acad Sci USA 111:3032–3037. doi:10.1073/pnas.1314421111
45. Ryazanov AG (2002) Elongation factor-2 kinase and its newly discovered relatives. FEBS Lett 514:26–29. doi:10.1016/S0014-5793(02)02299-8
46. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M et al (2002) Differences in cerebral metabolic impairment between early and late onset types of Alzheimer’s disease. J Neurol Sci 200:27–32. doi:10.1016/S0022-510X(02)00114-4
47. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M (2011) AMP-activated protein kinase: a potential player in Alzheimer’s disease. J Neurochem 118:460–474. doi:10.1111/j.1471-4159.2011.07331.x
48. Saraiva LM, Seixas da Silva GS, Galina A, da-Silva WS, da-Silva WS, Klein WL, Ferreira ST et al (2010) Amyloid-beta triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One 5:e15230. doi:10.1371/journal.pone.0015230
49. Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP et al (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617. doi:10.1016/j.nbd.2004.10.022
50. Sawin ER, Ranganathan R, Horvitz HR (2000) C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 26:619–631. doi:10.1016/S0896-6273(00)81199-X
51. Scheetz AJ, Nairn AC, Constantine-Paton M (2000) NMDA receptor-mediated control of protein synthesis at developing synapses. Nat Neurosci 3:211–216. doi:10.1038/72915
52. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
53. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106–113. doi:10.1016/j.bbr.2008.02.016
54. Selkoe DJ (2013) The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann Neurol 74:328–336. doi:10.1002/ana.24001
55. Selkoe DJ, Schenk D (2003) Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43:545–584
56. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. doi:10.1101/cshperspect.a006189
57. Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM (2007) Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 55:648–661. doi:10.1016/j.neuron.2007.07.030
58. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800
59. Tremblay RG, Sikorska M, Sandhu JK, Lanthier P, Ribecco-Lutkiewicz M, Bani-Yaghoub M (2010) Differentiation of mouse Neuro 2A cells into dopamine neurons. J Neurosci Methods 186:60–67. doi:10.1016/j.jneumeth.2009.11.004
60. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H et al (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79:887–902. doi:10.1016/j.neuron.2013.06.036
61. Vandal M, White PJ, Tournissac M, Tremblay C, St-Amour I, Drouin-Ouellet J et al (2016) Impaired thermoregulation and beneficial effects of thermoneutrality in the 3xTg-AD model of Alzheimer’s disease. Neurobiol Aging 43:47–57. doi:10.1016/j.neurobiolaging.2016.03.024
62. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 28:13574–13581. doi:10.1523/JNEUROSCI.4099-08.2008
63. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A et al (1999) Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. JBiolChem 274:25945–25952
64. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B et al (2002) Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133–140. doi:10.1016/S0006-8993(01)03058-X
65. Wilcock DM, Gordon MN, Morgan D (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1:1591–1595. doi:10.1038/nprot.2006.277
66. Wisniewski T, Goni F (2015) Immunotherapeutic approaches for Alzheimer’s disease. Neuron 85:1162–1176. doi:10.1016/j.neuron.2014.12.064
67. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL et al (2006) Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26:13102–13113. doi:10.1523/JNEUROSCI.3448-06.2006
68. Xie H, Hou S, Jiang J, Sekutowicz M, Kelly J, Bacskai BJ (2013) Rapid cell death is preceded by amyloid plaque-mediated oxidative stress. Proc Natl Acad Sci USA 110:7904–7909. doi:10.1073/pnas.1217938110